Sanofi-Aventis files pandemic H1N1 vaccine in US
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has become the first company to submit a supplemental NDA to the US FDA for its monovalent pandemic H1N1 vaccine and has also begun US clinical trials testing the benefits of adding an adjuvant to the vaccine.